Archrock Inc. AROC 深 滬
等待開盤 04-02 09:30:00 美东时间
34.13
-0.670
-1.93%
華盛通- 最 高34.66
- 今 開34.50
- 成交量 172.38万股
- 最 低 33.83
- 昨 收 34.80
- 總市值 59.81亿
- 52周最高 37.725
- 市盈率 靜 18.67
- 換手率 0.98%
- 52周最低 20.74
- 委 比 -60.00%
- 總股本 1.75亿
- 歷史最高 37.725
- 量 比 0.99
- 振 幅 2.39%
- 歷史最低 -7.7055
- 每 手 1
- 風險率 4.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Archrock CFO Doug Aron plans retirement by end of FY2026; executive search begins for successor
Archrock CFO Doug Aron plans retirement by end of FY2026; executive search begins for successor Archrock said Senior Vice President and Chief Financial Officer Douglas S. Aron plans to retire by the end of 2026 or when a successor is named. The company has engaged an executive search firm to identif
03-26 08:58
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monda
03-16 18:00
Wells Fargo Maintains Overweight on Archrock, Raises Price Target to $40
Wells Fargo analyst Michael Blum maintains Archrock (NYSE:AROC) with a Overweight and raises the price target from $39 to $40.
03-13 22:22
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Demystifying Archrock: Insights From 4 Analyst Reviews
During the last three months, 4 analysts shared their evaluations of Archrock (...
03-05 22:01
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
